Biomea Fusion
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 103
- Market Cap
- -
- Website
- http://biomeafusion.com
- Introduction
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
Biomea Fusion's BMF-650 Demonstrates Significant Weight Loss in Primate Study, Advancing Toward Clinical Trials
Biomea Fusion's oral GLP-1 receptor agonist BMF-650 achieved 12% and 15% weight reduction in obese cynomolgus monkeys over 28 days at doses of 10 mg/kg and 30 mg/kg respectively.
Biomea Fusion's BMF-500 Shows Promising Results in Relapsed/Refractory Acute Leukemia Phase I Trial
Preliminary data from the COVALENT-103 Phase I trial reveals BMF-500, a covalent FLT3 inhibitor, demonstrates clinical activity in heavily pretreated relapsed/refractory acute leukemia patients, with 81.8% of evaluable patients showing response.
Biomea Fusion Pivots to Diabetes and Obesity, Prioritizing Icovamenib Development
Biomea Fusion shifts strategic focus to diabetes and obesity medicines, with icovamenib and BMF-650 as core assets.
Biomea Fusion's Icovamenib Shows Promise in Phase II Trial for Type 2 Diabetes
Icovamenib met the primary endpoint in the COVALENT-111 trial, demonstrating a statistically significant, placebo-corrected reduction in HbA1c levels in type 2 diabetes patients.
Biomea Fusion's Icovamenib Shows Promise in Type 2 Diabetes Trial
Biomea Fusion is set to release topline results from its COVALENT-111 phase IIb trial of Icovamenib in approximately 200 patients with type 2 diabetes.
Biomea Fusion Announces Topline Results from Phase II COVALENT-111 Trial
Biomea Fusion is set to release topline results from its Phase II COVALENT-111 clinical trial, which evaluates a novel covalent menin inhibitor.
Biomea Fusion Announces Topline Results from Phase II COVALENT-111 Trial of Icovamenib in Type 2 Diabetes
Biomea Fusion will host a conference call on December 17, 2024, to present topline results from the Phase II COVALENT-111 trial of icovamenib in type 2 diabetes.
FDA Approves Syndax's Revuforj, a First-in-Class Menin Inhibitor for Acute Leukemia
The FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for adults and children with relapsed or refractory acute leukemia with KMT2A rearrangement.
Icovamenib Shows Promise in Insulin-Deficient Type 2 Diabetes Patients
Icovamenib demonstrates a significant reduction in HbA1c levels in type 2 diabetes patients with insulin deficiency, with an 83% response rate.
Biomea Fusion Anticipates Key Data Readouts for Icovamenib in Diabetes Trials
Biomea Fusion is set to release topline 26-week data from the Phase IIb COVALENT-111 trial, involving approximately 200 type 2 diabetes patients, in December 2024.